Pravin U Dugel, MD
Retinal Associates of Arizona
—
HAWK & HARRIER: 48–week Results Of 2 Multi-Centered, Randomized, Double-Masked Trials of
Brolucizumab Versus Aflibercept For Neovascular AMD and promising future treatments